SIGA Technologies, Inc. is a development stage biotechnology company. Its focus is on the discovery, development and commercialization of vaccines, antibiotics and novel anti-infectives for serious infectious diseases. Its lead vaccine candidate is for the prevention of group A streptococcal pharyngitis or "strep throat." The Company is developing a technology for the mucosal delivery of its vaccines which may allow those vaccines to activate the immune system at the mucus lined surfaces of the body the mouth, the nose, the lungs and the gastrointestinal and urogenital tracts the sites of entry for most infectious agents.